P. R. Wheater, B. Young, and G. O'dowd, Atlas d'histologie fonctionnelle de Wheater, 2015.

F. Binder-foucard, A. Belot, and P. Delafosse, Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Etude à partir des registres des cancers du réseau Francim -Partie 1 : tumeurs solides, 2013.

R. J. Kurman, International Agency for Research on Cancer, WHO classification of tumours of female reproductive organs, 2014.

A. Gadducci, S. Cosio, and A. Romanini, The management of patients with uterine sarcoma: a debated clinical challenge, Crit Rev Oncol Hematol, vol.65, pp.129-142, 2008.

S. E. Brooks, M. Zhan, and T. Cote, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989-1999, Gynecol Oncol, vol.93, pp.204-208, 2004.

M. R. Nucci, Practical issues related to uterine pathology: endometrial stromal tumors, Mod Pathol, vol.29, pp.92-103, 2016.

J. A. Bennett, V. Nardi, and M. Rouzbahman, Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum, Mod Pathol, vol.30, pp.1489-1503, 2017.

S. Croce, . Kock-l-de, and T. Boshari, Uterine Tumor Resembling Ovarian Sex Cord Tumor (utrosct) Commonly Exhibits Positivity With Sex Cord Markers Foxl2 and Sf-1 but Lacks foxl2 and dicer1 Mutations, Int J Gynecol Pathol, vol.35, pp.301-308, 2016.

S. Chiang, P. N. Staats, and J. Senz, Foxl2 Mutation is Absent in Uterine Tumors Resembling Ovarian Sex Cord Tumors, Am J Surg Pathol, vol.39, pp.618-623, 2015.

O. Fadare, Heterologous and Rare Homologous Sarcomas of the Uterine Corpus: A Clinicopathologic Review, Adv Anat Pathol, vol.18, pp.60-74, 2011.

J. K. Schoolmeester, J. Carlson, and G. L. Keeney, Alveolar Soft Part Sarcoma of the Female Genital Tract: A Morphologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases With Emphasis on its Distinction From Morphologic Mimics, Am J Surg Pathol, vol.41, pp.622-632, 2017.

J. K. Schoolmeester, B. E. Howitt, and M. S. Hirsch, Perivascular Epithelioid Cell Neoplasm (pecoma) of the Gynecologic Tract: Clinicopathologic and Immunohistochemical Characterization of 16 Cases, Am J Surg Pathol, vol.38, pp.176-188, 2014.

J. K. Schoolmeester, L. N. Dao, and W. R. Sukov, TFE3 Translocation Associated Perivascular Epithelioid Cell Neoplasm (PEComa) of the Gynecologic Tract: Morphology, Immunophenotype, Differential Diagnosis, Am J Surg Pathol, vol.39, pp.394-404, 2015.

B. L. Harlow, N. S. Weiss, and S. Lofton, The epidemiology of sarcomas of the uterus, J Natl Cancer Inst, vol.76, pp.399-402, 1986.

J. R. Toro, L. B. Travis, and H. J. Wu, Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases, Int J Cancer, vol.119, pp.2922-2930

D. , A. E. Prat, and J. , Uterine sarcomas: A review, Gynecol Oncol, vol.116, pp.131-139, 2010.

V. M. Abeler, O. Røyne, and S. Thoresen, Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients, Histopathology, vol.54, pp.355-364, 2009.

P. Ip and A. Cheung, Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential, Best Pract Res Clin Obstet Gynaecol, vol.25, pp.691-704, 2011.

E. Oliva, M. Carcangiu, and S. Carinelli, Mesenchymal tumours. Leiomyosarcoma. In: Kurman RJ, International Agency for Research on Cancer, WHO classification of tumours of female reproductive organs, pp.139-141, 2014.

C. Parra-herran, J. K. Schoolmeester, and L. Yuan, Myxoid Leiomyosarcoma of the Uterus: A Clinicopathologic Analysis of 30 Cases and Review of the Literature With Reappraisal of Its Distinction From Other Uterine Myxoid Mesenchymal Neoplasms, Am J Surg Pathol, vol.40, pp.285-301, 2016.

S. W. Bell, R. L. Kempson, and M. R. Hendrickson, Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases, Am J Surg Pathol, vol.18, pp.535-558, 1994.

E. Oliva, Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia, Mod Pathol, vol.29, pp.104-120, 2015.

E. Oliva, M. Carcangiu, and S. Carinelli, WHO Classification of tumours of Female reproductive organs. Lyon: International Agency for Research on Cancer, pp.135-147, 2014.

D. Lim, T. Alvarez, and M. R. Nucci, Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma, Am J Surg Pathol, vol.37, pp.650-658, 2013.

E. Oliva, R. H. Young, and M. B. Amin, An Immunohistochemical Analysis of Endometrial Stromal and Smooth Muscle Tumors of the guterus: A Study of 54 Cases Emphasizing the Importance of Using a Panel Because of Overlap in Immunoreactivity for Individual Antibodies, Am J Surg Pathol, vol.26, pp.403-412, 2002.

M. Hosh, S. Antar, and A. Nazzal, Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database, Int J Gynecol Cancer Off J Int Gynecol Cancer Soc, vol.26, pp.1098-1104, 2016.

S. Lange, N. Pluchino, and A. Fehlmann, Prevalence of undiagnosed uterine leiomyosarcoma in women undergoing hysterectomy or myomectomy for benign indications, Eur J Obstet Gynecol Reprod Biol, 2017.

E. A. Pritts, The prevalence of occult leiomyosarcoma in women undergoing presumed fibroid surgery and outcomes after morcellation, Curr Opin Obstet Gynecol, p.1, 2017.

S. Ricci, R. L. Stone, and A. N. Fader, Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation, Gynecol Oncol, vol.145, pp.208-216, 2017.

O. Lavie, O. Barnett-griness, and S. A. Narod, The risk of developing uterine sarcoma after tamoxifen use, Int J Gynecol Cancer, vol.18, pp.352-356, 2008.

A. S. Felix, L. S. Cook, and M. M. Gaudet, The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium, Br J Cancer, vol.108, pp.727-734, 2013.

B. Seagle, J. Sobecki-rausch, and A. E. Strohl, Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study, Gynecol Oncol, vol.145, pp.61-70, 2017.

D. S. Kapp, J. Y. Shin, and J. K. Chan, Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy, Cancer, vol.112, pp.820-830, 2008.

D. Nasioudis, E. Chapman-davis, and M. Frey, Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma, J Gynecol Oncol, vol.28, 2017.

M. Si, L. Jia, and K. Song, Role of Lymphadenectomy for Uterine Sarcoma: A Meta-Analysis, Int J Gynecol Cancer Off J Int Gynecol Cancer Soc, vol.27, pp.109-116, 2017.

R. D. Littell, L. Tucker, R. Bennett, and T. , Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes, Gynecol Oncol, vol.147, pp.11-17, 2017.

N. S. Reed, C. Mangioni, and H. Malmström, Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874), Eur J Cancer, vol.44, pp.808-818, 2008.

C. Bartosch, M. Afonso, and A. S. Pires-luís, Distant Metastases in Uterine Leiomyosarcomas: The Wide Variety of Body Sites and Time Intervals to Metastatic Relapse, Int J Gynecol Pathol, vol.36, pp.31-41, 2017.

A. Gadducci, Prognostic factors in uterine sarcoma, Best Pract Res Clin Obstet Gynaecol, vol.25, pp.783-795, 2011.

O. Zivanovic, M. M. Leitao, and A. Iasonos, Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems, J Clin Oncol, vol.27, pp.2066-2072, 2009.

J. Prat, FIGO staging for uterine sarcomas, Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet, vol.104, pp.177-178, 2009.

R. L. Giuntoli, C. R. Lessard-anderson, and M. A. Gerardi, Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma, Int J Gynecol Cancer Off J Int Gynecol Cancer Soc, vol.23, pp.869-876, 2013.

A. F. Pellanda, D. Bari, B. Deniaud-alexandre, and E. , Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study, Chin J Cancer Res, vol.29, pp.521-532, 2017.

R. L. Giuntoli, D. S. Metzinger, and C. S. Dimarco, Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy?, Gynecol Oncol, vol.89, pp.460-469, 2003.

P. Pautier, C. Genestie, and A. Rey, Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma, Cancer, vol.88, pp.1425-1431, 2000.

O. Zivanovic, L. M. Jacks, and A. Iasonos, A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma, Cancer, vol.118, pp.660-669, 2012.

A. Iasonos, E. Z. Keung, and O. Zivanovic, External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma, Cancer, vol.119, pp.1816-1822, 2013.

S. E. Akhan, E. Yavuz, and A. Tecer, The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study, Gynecol Oncol, vol.99, pp.36-42, 2005.

K. Bodner, B. Bodner-adler, and O. Kimberger, Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters, Anticancer Res, vol.23, pp.729-732, 2003.

I. H. Hewedi, N. A. Radwan, and L. S. Shash, Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors, Diagn Pathol, vol.7, p.1, 2012.

Y. Liang, X. Zhang, and X. Chen, Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma, Int J Clin Exp Pathol, vol.8, pp.7196-7202, 2015.

M. M. Leitao, R. A. Soslow, and D. Nonaka, Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma, Cancer, vol.101, pp.1455-1462, 2004.

M. M. Leitao, M. L. Hensley, and R. R. Barakat, Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma, Gynecol Oncol, vol.124, pp.558-562, 2012.

B. Davidson, M. L. Kjaereng, and M. Førsund, Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma, Am J Clin Pathol, vol.145, pp.449-458, 2016.

J. Krishnamurthy, C. Torrice, and M. R. Ramsey, Ink4a/Arf expression is a biomarker of aging, J Clin Invest, vol.114, pp.1299-1307, 2004.

P. P. Ip, D. Lim, and A. Cheung, Immunoexpression of p16 in uterine leiomyomas with infarct-type necrosis: an analysis of 35 cases, Histopathology, vol.71, pp.743-750, 2017.

C. J. O'neill and W. G. Mccluggage, p16 expression in the female genital tract and its value in diagnosis, Adv Anat Pathol, vol.13, pp.8-15, 2006.

O. Kawaguchi-ken-ichi, S. Yoshinao, and . Tsuyoshi, Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis, J Pathol, vol.201, pp.487-495, 2003.

B. Bodner-adler, K. Bodner, and K. Czerwenka, Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis, Gynecol Oncol, vol.96, pp.62-66, 2005.

S. Kanayama, H. Oi, and R. Kawaguchi, Immunohistochemical Analysis of p16 Expression in Uterine Smooth Muscle Tumors, Open J Obstet Gynecol, vol.05, pp.688-697, 2015.

L. Chen and B. Yang, Immunohistochemical Analysis of P16, P53, and Ki-67 Expression in Uterine Smooth Muscle Tumors, Int J Gynecol Pathol, vol.27, pp.326-332, 2008.

K. A. Atkins, N. Arronte, and C. J. Darus, The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors, Am J Surg Pathol, vol.32, pp.98-102, 2008.

N. U. Ünver, M. F. Acikalin, and Ü. Öner, Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors, Arch Gynecol Obstet, vol.284, pp.483-490, 2011.

H. Y. Cao, S. Yang, and S. Wang, Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis, Genet Mol Res GMR, vol.16, 2017.

B. Vogelstein, D. Lane, and A. J. Levine, Surfing the p53 network, Nature, vol.408, pp.307-310, 2000.

R. Nenutil, J. Smardova, and S. Pavlova, Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry, J Pathol, vol.207, pp.251-259, 2005.

L. J. Layfield, K. Liu, and R. Dodge, Uterine Smooth Muscle Tumors, Arch Pathol Lab Med, vol.124, pp.221-227, 2000.

T. H. Niemann, S. S. Raab, and J. C. Lenel, p53 protein overexpression in smooth muscle tumors of the uterus, Hum Pathol, vol.26, pp.375-379, 1995.

R. Blom, C. Guerrieri, and O. Stål, Leiomyosarcoma of the Uterus: A Clinicopathologic, DNA Flow Cytometric, p53, and mdm-2 Analysis of 49 Cases, Gynecol Oncol, vol.68, pp.54-61, 1998.

A. Abeshouse, C. Adebamowo, and S. N. Adebamowo, Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas, Cell, vol.171, pp.950-965, 2017.

H. Tsuyoshi and Y. Yoshida, Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma, Cancer Sci, 2018.

K. R. Mittal, F. Chen, and J. J. Wei, Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyomalike areas, Mod Pathol, vol.22, pp.1303-1311, 2009.

N. Mäkinen, M. Aavikko, and T. Heikkinen, Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12, PLoS Genet, vol.12, 2016.

G. Pérot, S. Croce, and A. Ribeiro, MED12 Alterations in Both Human Benign and Malignant Uterine Soft Tissue Tumors, PLoS ONE, vol.7, 2012.

N. Makinen, M. Mehine, and J. Tolvanen, MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas, Science, vol.334, pp.252-255, 2011.

H. Yanai, Y. Wani, and K. Notohara, Uterine leiomyosarcoma arising in leiomyoma: clinicopathological study of four cases and literature review, Pathol Int, vol.60, pp.506-509, 2010.

J. H. Kim, Y. J. Choi, and D. C. Kim, Leiomyosarcoma arising in a patient with prior mitotically active leiomyoma, J Obstet Gynaecol Res, vol.36, pp.187-190, 2010.

A. H. Beck, C. Lee, and D. M. Witten, Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling, Oncogene, vol.29, pp.845-854, 2010.

X. Guo, V. Y. Jo, and A. M. Mills, Clinically relevant molecular subtypes in leiomyosarcoma, Clin Cancer Res Off J Am Assoc Cancer Res, vol.21, pp.3501-3511, 2015.

T. Cuppens, M. Moisse, and J. Depreeuw, Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways, Int J Cancer, 2017.

B. Davidson and F. Micci, Molecular characteristics of uterine sarcomas, Expert Rev Mol Diagn, vol.17, pp.515-522, 2017.

F. Amant, M. De-la-rey, and C. M. Dorfling, PTEN mutations in uterine sarcomas, Gynecol Oncol, vol.85, pp.165-169, 2002.

J. W. Ahn, M. Coldwell, and S. Bint, Array Comparative Genomic Hybridization (Array CGH) for Detection of Genomic Copy Number Variants, J Vis Exp JoVE, 2015.

M. Raish, M. Khurshid, and M. A. Ansari, Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization, J Cancer Res Clin Oncol, vol.138, pp.1173-1186, 2012.

J. Hu, V. Khanna, and M. Jones, Genomic alterations in uterine leiomyosarcomas: Potential markers for clinical diagnosis and prognosis, Genes Chromosomes Cancer, vol.31, pp.117-124, 2001.

Y. Cho, S. Bae, and M. Koo, Array comparative genomic hybridization analysis of uterine leiomyosarcoma, Gynecol Oncol, vol.99, pp.545-551, 2005.

S. Croce, A. Ribeiro, and C. Brulard, Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions, Mod Pathol, vol.28, pp.1001-1010, 2015.

S. Croce, A. Ducoulombier, and A. Ribeiro, Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors, Mod Pathol Off J U S Can Acad Pathol Inc, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01926566

E. M. Lutz, S. Shen, and M. Mackay, Structure of the human VIPR2 gene for vasoactive intestinal peptide receptor type 2, FEBS Lett, vol.458, pp.197-203, 1999.

T. W. Moody, B. Nuche-berenguer, and R. T. Jensen, VIP/PACAP, and their receptors and cancer, Curr Opin Endocrinol Diabetes Obes, vol.23, pp.38-47, 2016.

L. Dickson, K. Finlayson, and . Vpac, From ligands to function, Pharmacol Ther, vol.121, pp.294-316, 2009.

I. Langer, Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies, Front Endocrinol, vol.3, 2012.

J. C. Reubi, U. Läderach, and B. Waser, Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor Subtypes in Human Tumors and Their Tissues of Origin1, Cancer Res, vol.60, pp.3105-3112, 2000.

J. Yuan, J. C. Sha, and W. , A competitive PCR assay confirms the association of a copy number variation in the VIPR2 gene with schizophrenia in Han Chinese, Schizophr Res, vol.156, pp.66-70, 2014.

O. Maiques, M. Santacana, and J. Valls, Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues, Hum Pathol, vol.45, pp.522-532, 2014.

X. Dolcet, D. Llobet, and J. Pallares, FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis, Lab Invest, vol.85, pp.885-894, 2005.

X. Yue, H. Utsunomiya, and J. Akahira, Expression of steroid and xenobiotic receptor in uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma, Oncol Lett, vol.5, pp.835-839, 2013.

J. M. Harvey, G. M. Clark, and C. K. Osborne, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.17, pp.1474-1481, 1999.

R. Leake, D. Barnes, and S. Pinder, Immunohistochemical detection of steroid receptors in breast cancer: a working protocol, J Clin Pathol, vol.53, pp.634-635, 2000.

H. Lassus, A. Leminen, and J. Lundin, Distinct subtypes of serous ovarian carcinoma identified by p53 determination?????Supplementary data associated with this article can be, Gynecol Oncol, vol.91, pp.504-512, 2003.

M. Köbel, A. M. Piskorz, and S. Lee, Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma, J Pathol Clin Res, vol.2, pp.247-258, 2016.

M. Köbel, B. M. Ronnett, and N. Singh, Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility, Int J Gynecol Pathol, p.1, 2018.

P. Lagarde, G. Pérot, and A. Kauffmann, Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors, Clin Cancer Res, vol.18, pp.826-838, 2012.

S. Schulz, A. Mann, and B. Novakhov, VPAC2 receptor expression in human normal and neoplastic tissues: evaluation of the novel MAB SP235, Endocr Connect, vol.4, pp.18-26, 2015.

. St, . Hilaire-r-c, S. N. Murthy, and P. J. Kadowitz, Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation, Peptides, vol.31, pp.1517-1522, 2010.

V. Petkov, W. Mosgoeller, and R. Ziesche, Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension, J Clin Invest, vol.111, pp.1339-1346, 2003.

K. Maruno, A. Absood, and S. I. Said, Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo, Proc Natl Acad Sci, vol.95, pp.14373-14378, 1998.

C. Reubi-jean, Vitro Evaluation of VIP/PACAP Receptors in Healthy and Diseased Human Tissues: Clinical Implications, vol.921, pp.1-25, 2006.

T. Moody and I. Gozes, Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer, Curr Pharm Des, vol.13, pp.1099-1104, 2007.

B. Collado, M. J. Carmena, and M. Sánchez-chapado, Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: Antagonistic action of a growth-hormone-releasing hormone analog, Int J Oncol, vol.26, pp.1629-1635, 2005.

M. Szilasi, A. Buglyo, and A. Treszl, Gene expression of vasoactive intestinal peptide receptors in human lung cancer, Int J Oncol, vol.39, pp.1019-1024, 2011.

T. W. Moody, F. Zia, and M. Draoui, A vasoactive intestinal peptide antagonist inhibits nonsmall cell lung cancer growth, Proc Natl Acad Sci, vol.90, pp.4345-4349, 1993.

P. J. Van-diest, P. Van-dam, and S. C. Henzen-logmans, A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of CancerGynaecological Cancer Cooperative Group, J Clin Pathol, vol.50, pp.801-804, 1997.

Z. Rekasi, J. L. Varga, and A. V. Schally, Antagonists of Growth Hormone-Releasing Hormone and Vasoactive Intestinal Peptide Inhibit Tumor Proliferation by Different Mechanisms: Evidence from in Vitro Studies on Human Prostatic and Pancreatic Cancers, Endocrinology, vol.141, pp.2120-2128, 2000.

A. Plonowski, J. L. Varga, and A. V. Schally, Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity, Int J Cancer, vol.98, pp.624-629

C. De-deontologie, S. Medicale, and . Hippocrate,

, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je donnerai mes soins à l'indigent et à quiconque me les demandera

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés

, Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

, que je sois déshonorée et méprisée si j'y manque